Eagle Pharmaceuticals Dividend
Dividend criteria checks 0/6
Eagle Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | US$0.92 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Jul 13Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia
Oct 12Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Sep 27Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Aug 18Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be
Aug 15Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M
Aug 09These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Jul 06Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price
Apr 29Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?
Dec 16Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package
Jul 06Eagle Pharmaceuticals: A Potential Reopening Play
Jun 16Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue
May 10Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma
Apr 30Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt
Apr 15Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price
Mar 25Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if EGRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EGRX's dividend payments have been increasing.
Dividend Yield vs Market
Eagle Pharmaceuticals Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (EGRX) | n/a |
Market Bottom 25% (US) | 1.6% |
Market Top 25% (US) | 4.8% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (EGRX) | n/a |
Notable Dividend: Unable to evaluate EGRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EGRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate EGRX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EGRX has not reported any payouts.